Kimball Electronics (KE) Q4 FY26 earnings call: guidance and Q&A

Could you provide more color on the Medical segment's performance, especially the strength in Asia and Europe, and the reasons for the North America slowdown?

The strength in Asia and Europe is a continuation of consistent double-digit growth trends. The North America slowdown is primarily due to tough comparisons from Q4 FY25, which included one-time inventory builds for facility closures and work transfers, not a fundamental production slowdown.

“In Q4 of '25, we had 2 onetime builds for customers. One was related to a transfer of work and one was related to a facility closure where they needed to build up inventory in support of that. And so if you adjust for those things, a normalized quarter-v-quarter FY '26, FY '25 is closer to 10%.”

asked by Brett Fishbin · answered by Jana Croom

What are the key drivers for the high single-digit to low double-digit organic growth expected in Medical for FY27, and what role will the new Indy facility play?

Growth is expected across most medical product categories (respiratory care, surgical devices, in vitro diagnostics, imaging, drug delivery). The Indy facility's impact will be gradual, initially focusing on transferring existing production rather than immediate incremental growth. Significant synergies are expected from the Helvoet acquisition, leveraging combined footprints and technologies for larger programs.

“I wouldn't expect you'll see a big impact in '27 from Indianapolis just because new programs take time to ramp. We may have some good opportunities with lift and shift programs that are already in market that we could move there, but those will take some time as well. So it's really a more broad-based improvement kind of building on the momentum that we saw this year.”

asked by Brett Fishbin · answered by Richard Phillips

Helvoet's calendar year 2025 revenue was around $56 million, but FY27 guidance is $60 million. Are there transition impacts or near-term headwinds affecting its growth rate?

The difference is primarily due to FX translation impacts from INR and Euro to USD for the fiscal year. There are no significant transition impacts or headwinds; the focus is on business as usual and unlocking cross-selling opportunities. The $60 million contribution still represents strong top-line growth.

“So there are really 2 impacts. One is actually FX and the FX translation from the INR and the euro on the U.S. dollar. That's going to be an impact for our fiscal year. And -- so not really a transition impact because we've been really, really thoughtful about not interrupting what they've got going on in terms of sales and actually trying to unlock opportunity there in terms of cross-selling opportunities geographically.”

asked by Brett Fishbin · answered by Jana Croom

Is the drag from the Indianapolis facility ramp truly offset by Helvoet, and what is the exact timeline for the ramp-up and revenue generation?

The drag from Indianapolis is estimated at $6.5 million to $7 million, which is roughly offset by Helvoet's accretive benefit. The facility opened in February, but revenue generation will start in Q4 calendar year 2026 (Q2 FY27). The 18-month ramp-up timeline is for new programs, starting from when production commences, not from the building's opening.

“So think of it this way. You've got all of the associated depreciation, plant costs, just all the things associated utility expense, et cetera, for a facility that's empty. It's not that there won't be a drag in FY '28. It's that eventually, it will produce enough revenue to overcome the drag.”

asked by Michael Crawford · answered by Jana Croom

Given the current low leverage, what is the optimal capital structure, and what are the capital allocation priorities going forward?

An optimal leverage ratio is between 1.5x and 2x debt to EBITDA. Capital allocation priorities include supporting organic growth, continuing the share repurchase program (with $24.4 million remaining), and maintaining dry powder for inorganic opportunities. While the company could temporarily exceed 3x leverage for the right M&A, the focus is on paying down debt from the Helvoet acquisition to preserve flexibility.

“So somewhere between 1.5 and 2x feels good for our business, but you need to keep your balance sheet strong enough when incremental growth opportunities that are inorganic present themselves, you've got the dry powder to act. So you're going to see the cost of the acquisition show up on our balance sheet in Q1. We're going to be actively utilizing our operating cash flow and global cash repatriation options to pay that down so that we can continue to have dry powder should another inorganic opportunity present itself, plus we've got $50 million of organic CapEx needs that we need to deploy.”

asked by Michael Crawford · answered by Jana Croom

Could you detail your thoughts on the Automotive segment, particularly when it might turn positive, considering regional and product differences?

The segment is stabilizing after declines driven by lower EV demand, not lost programs. Europe is strong with new steering and braking programs ramping up. China is competitive but relationships remain strong, and the company continues to win next-gen programs. Management expects a market-driven return to growth eventually and is staying close to customers.

“The decline is really, as I mentioned earlier on the call, has been driven by low demand for EV programs that we won. It's not programs that we lost. It's just programs that have underperformed in terms of the volumes that we originally anticipated. So we'll see how that continues to evolve with regulations and incentives and so on over time.”

asked by Derek Soderberg · answered by Richard Phillips

Is the 82-day cash conversion cycle sustainable with accelerating organic and inorganic growth, or do you anticipate changes?

The 82-day CCD was hard-won. Management anticipates some pressure on working capital and a slight increase in CCD in FY27 due to inventory disruption in the supply chain and customers requesting more inventory, leading to slower turns for certain components. This is factored into the FY27 guidance.

“I'm anticipating that there is going to be some pressure in working capital generally in FY '27. We've taken that into consideration as we're thinking about the guide for next year and the impact that it's going to have on the balance sheet, and we're managing through it with our -- but we're already seeing the impact. So if it rose a couple of days in FY '27, let me say that differently. We are planning for it to rise a few days in FY '27.”

asked by Derek Soderberg · answered by Jana Croom

Have there been any surprises, good or bad, post the Helvoet acquisition regarding customer retention, integration pace, or go-to-market strategy?

On balance, the experience has been very positive. Customer conversations have been good, confirming the retention of customers and the commitment to Helvoet's existing footprint. The integration process is proceeding as expected, with leaders and functions engaged. The most encouraging aspect has been the strong top-line synergy opportunities identified, leveraging the combined footprint and capabilities, with capital already being allocated to fund these initiatives.

“If anything, the top line synergy opportunities, which are very much still taking shape, have been really encouraging. And we're so early when exactly are they going to happen and where exactly will they be located and how big will they be is -- those are the things that we're working on. But the teams across both organizations are talking to every single week at least about a pretty impressive list of potential synergy opportunities, leveraging the combined footprint.”

asked by Unknown Analyst · answered by Richard Phillips